Skip to Main Content


Skip Nav Destination


Studies that investigate the immune system, its interactions with tumor cells, and opportunities to enhance the body's natural defenses against cancer

Latest in Immuno-oncology
Evan Rosenbaum, Kenneth Seier et al.
The association between immune-related AEs (irAEs) and outcome in patients with sarcoma is not known. We retrospectively reviewed a cohort of patients with advanced sarcoma treated with immune checkpoint blockade (ICB)-based therapy. Association of irAEs with survival was assessed using a Cox regression model that ...
Jian Ye, Weihua Guo et al.
Microsatellite stable (MSS) colorectal cancer (CRC) patients with liver metastases are resistant to immune checkpoint inhibitor (ICI) therapy, while about one-third of CRC patients without liver metastases, particularly those with lung-only metastases, respond to ICI. We analyzed primary CRC tumors and major metastatic ...
Mir Lim, Maishara Muquith et al.
Immune checkpoint inhibitors (ICI) can induce atypical tumor responses including pseudoprogression in a subset of patients who may benefit from treatment beyond progression. While ICIs have emerged as frontline treatments for hepatocellular carcinoma (HCC) and are associated with clinical benefit in a minority of ...
Jesus Amo-Aparicio, Adrian Dominguez et al.
Defining feature of pancreatic ductal adenocarcinoma (PDAC) that participates in the high mortality rate and drug resistance is the immune-tolerant microenvironment which enables tumors to progress unabated by adaptive immunity. In this study, we report that PDAC cells release CSF-1 to induce nucleotide-binding domain, ...
Richard W. Davis, IV, Astero Klampatsa et al.
Surgical cytoreduction for patients with malignant pleural mesothelioma (MPM) is used for selected patients as a part of multi-modality management strategy. Our group has previously described the clinical use of photodynamic therapy (PDT), a form of non-ionizing radiation, as an intraoperative therapy option for MPM. ...
Kyle M. Garland, Alexander J. Kwiatkowski et al.
It was recently found that patients with relapsing remitting multiple sclerosis exhibit widespread loss of adenosine-to-inosine (A-to-I) RNA editing, which contributes to the accumulation of immunostimulatory double-stranded Alu RNA in circulating leukocytes and an attendant increase in levels of proinflammatory cytokines ...
Valerie P. O'Brien, Yuqi Kang et al.
Mechanisms for Helicobacter pylori (Hp)-driven stomach cancer are not fully understood. In a transgenic mouse model of gastric preneoplasia, concomitant Hp infection and induction of constitutively active KRAS (Hp+KRAS+) alters metaplasia phenotypes and elicits greater inflammation than either perturbation alone. Gastric ...
Vina P. Nguyen, Katie M. Campbell et al.
Neoadjuvant combination immune checkpoint blockade and intralesional oncolytic virotherapy have the potential to activate antitumor responses in patients with breast cancer.
Kanika Jain, Ian C. Henrich et al.
Ewing sarcoma is a rare and deadly pediatric bone cancer for which survival rates and treatment options have stagnated for decades. Ewing sarcoma has not benefited from immunotherapy due to poor understanding of how its immune landscape is regulated. We recently reported that ubiquitin-specific protease 6 (USP6) functions ...
Sapna Yadavilli, Jeremy D. Waight et al.
In recent years, there has been considerable interest in mAb-based induction of costimulatory receptor signaling as an approach to combat cancer. However, promising nonclinical data have yet to translate to a meaningful clinical benefit. Inducible T-cell costimulator (ICOS) is a costimulatory receptor important for immune ...
Close Modal

or Create an Account

Close Modal
Close Modal